A New Pancreatic Cancer Drug Offers More Time—but Not a Cure

A New Pancreatic Cancer Drug Offers More Time—but Not a Cure
The FDA’s approval of daraxonrasib marks a major advance against one of the deadliest cancers, but it also highlights the limits of a treatment that extends survival without offering a cure.

Sold as Rasonque, the once-daily tablet is approved for patients with metastatic pancreatic cancer whose disease has not responded to chemotherapy. In Revolution Medicines’ clinical trials, median overall survival reached 13.2 months, compared with 6.7 months for chemotherapy—a striking improvement, though still a measure of additional time rather than recovery.

Federal health officials and pancreatic-cancer advocates presented the decision as a meaningful shift in a field long defined by poor outcomes. Acting FDA Commissioner Kyle Diamantas called it “a critical new option” for patients facing an “extraordinarily difficult and historically hard-to-treat cancer.” Anna Berkenblit of the Pancreatic Cancer Action Network went further, describing the approval as “the most significant advance” she had seen in pancreatic-cancer treatment.

The accounts differ less over the drug’s promise than over what that promise means. Supporters emphasize longer survival, improved quality of life and renewed momentum for research. Yet the treatment blocks cancer-growth signals rather than eradicating the disease, and its list price—$39,800 for a 30-day supply—could make access a serious concern despite assistance for some insured patients.

The supplied liberal-side material does not offer a competing view of the FDA decision; it concerns Salesforce’s defense of traditional software against artificial-intelligence disruption. That mismatch leaves the medical case largely uncontested in the available sources, while the central unresolved question is practical: how broadly patients will be able to obtain a costly therapy that promises more time, but not a cure.

Sources

FDA Approves Breakthrough Pancreatic Cancer Drug Proven to Extend Survival — “The drug nearly doubled median overall survival compared with chemotherapy, while officials and advocates described the approval as a major advance.”